中国癌症杂志2025，Vol.35Issue(3)：273-282,10.DOI:10.19401/j.cnki.1007-3639.2025.03.003
CDK4/6抑制剂后时代下的乳腺癌精准诊疗
Precision diagnosis and treatment of breast cancer in the post-CDK4/6 inhibitor era
摘要
Abstract
Cyclin-dependent kinase(CDK)4/6 inhibitors plus endocrine therapy represents the standard first-line treatment for patients with hormone receptor-positive,human epidermal growth factor receptor 2(HER2)-negative advanced breast cancer.The introduction of CDK4/6 inhibitors has significantly improved the prognosis of breast cancer patients.However,it has also brought new clinical challenges,such as disease progression and treatment resistance in many patients.Currently,there is a lack of standardized subsequent treatment options for patients whose disease progresses after CDK4/6 inhibitor combined with endocrine therapy.Endocrine therapy resistance can lead to tumor progression through estrogen receptor(ESR)-dependent or ESR-independent pathways.Novel endocrine agents have the potential to benefit breast cancer patients harboring ESR1 mutations.Patients with alterations in the phosphoinositide 3-kinase(PI3K)/protein kinase B(AKT)/mammalian target of rapamycin(mTOR)pathway may be particularly sensitive to targeted inhibitors of this pathway.Furthermore,newly approved or investigational antibody-drug conjugate(ADC),immunotherapy-based combinations,and novel cell cycle inhibitors have demonstrated promising anti-tumor activities.Precision medicine-based combination strategies not only expand clinical treatment options but also enable physicians to make personalized treatment decisions for patients.Biomarker-driven precision therapeutic strategies have emerged as a critical area of treatment development in the post-CDK4/6 inhibitor era.关键词
激素受体阳性晚期乳腺癌/细胞周期蛋白依赖性激酶4和6抑制剂/精准诊疗/内分泌治疗/靶向治疗/抗体药物偶联物Key words
Hormone receptor-positive advanced breast cancer/Cyclin-dependent kinase 4 and 6 inhibitor/Precision medicine/Endocrine therapy/Targeted therapy/Antibody-drug conjugate分类
医药卫生引用本文复制引用
李彬,陶中华,胡夕春..CDK4/6抑制剂后时代下的乳腺癌精准诊疗[J].中国癌症杂志,2025,35(3):273-282,10.基金项目
国家自然科学基金(82473071) （82473071）
上海市抗癌协会"翱翔"计划(SACA-AX202402). National Natural Science Foundation of China(82473071) （SACA-AX202402）
Shanghai Anticancer Association SOAR PROJECT(SACA-AX202402). （SACA-AX202402）
